Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 vs HRIG for Rabies PEP
NCT04644484Phase 3Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of zamerovimab + mazorelvimab in rabies, sponsored by Xingmeng Biopharmaceutical. Started Sep 2020; status: completed.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on NCT04644484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644484.